ISPE announced its 2017 Biopharmaceutical Manufacturing Conference, taking place 4 – 6 December in San Francisco, California. This year's event will expand the conversation beyond manufacturing capacity needs to address innovative operational and process development strategies to speed preparations toward launch readiness.
“The industry’s ability to operationalize their investments in new and re-designed facilities is central to its success in providing an adequate supply of products to meet patient needs,” said John Bournas, ISPE CEO and President. “As companies prepare for the increased demand for facility improvements, design and manufacturing resources, operational agility and faster time to launch readiness are two key factors that will have an impact on their success.”
The 2017 ISPE Biopharmaceutical Manufacturing Conference features three education tracks with comprehensive sessions offering solutions from industry, regulatory, and academic experts. Attendees will gain insight into innovative strategies and approaches designed to improve operational agility and preparation time for launch readiness. Hear regulatory perspectives on how to implement new manufacturing capabilities and advancements to insure timely licensure.
Conference highlights include:
Learn more about the 2017 ISPE Biopharmaceutical Manufacturing Conference.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...
